Structure Therapeutics (GPCR) jumps higher here as a large trade buys 4500 July $40/$90 call spreads at $11.50. GPCR is a $1.8B biotech that has been recovering off lows from news in December that sold the stock off after it provided a comprehensive GSBR-1290 program update including clinically meaningful proof-of-concept data from Phase 2a Clinical Study. The Company is focused on discovering and developing oral treatments for chronic metabolic and pulmonary conditions. It develops oral small molecule therapeutics for the treatment of various diseases, including those impacting the metabolic, cardiovascular, and pulmonary systems. Analysts are overall bullish with an average price target of $82. Short float is 7% but as also declined about -19% in the last 3 months, often a bullish sign in biotechs. The call spread strikes are showing confidence as the buyer is long the ITM $40 strike and sold the $90 stirke which is a delta near 20 and also the max strike in the expiration of July. The buyer sees potential big upside into Summertime with the former all time highs from last year at 75 a definite target potential.